Reproducibility of fNIRS Parameters During Walking

Overview

Brain activation can be studied using the Functional Near InfraRed Spectroscopy (fNIRS). It was shown that CPF activation during walking and during dual task could be different in stroke patients and in healthy subjects. To date, fNIRS reliability is not completely established during walking and during dual task. Therefore, this study will examine the reproducibility of fNIRS parameters during simple walking and during dual task in healthy subjects and in stroke patients.

Full Title of Study: “Reproducibility of fNIRS Parameters During Walking in Stroke Patients and Healthy Subjects”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 2024

Detailed Description

A fNIRS system will be used to measure the CPF activation. The subjects will walk at their preferred speed on 10 m 3 times and while doing a cognitive task (dual task) 3 times also (in a random order). The same test will be repeated five minutes later. The fNIRS system will be retired and the same test will be repeated 10 min later.

Interventions

  • Procedure: Functional Near-Infrared Spectroscopy (fNIRS)
    • All participants will undergo Functional Near-Infrared Spectroscopy (fNIRS). The hemodynamic response in CPF will be measured using an Octomon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant’s forehead.

Arms, Groups and Cohorts

  • Experimental: Functional Near-Infrared Spectroscopy (fNIRS) acquisitions
    • The hemodynamic response in CPF will be measured using an Octomon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant’s forehead.

Clinical Trial Outcome Measures

Primary Measures

  • Oxyhemoglobin (HbO) variations during simple walking and during dual task
    • Time Frame: Day 0
    • HbO will be measured by the NIR spectrometry technique continuously at rest and during walking. This technique allows to measure the variations of HbO concentration by measuring the variations of light absorption by the explored tissues.
  • Deoxyhemoglobin (HbR) variations during simple walking and during dual task
    • Time Frame: Day 0
    • HbR will be measured by the NIR spectrometry technique continuously at rest and during walking. This technique allows to measure the variations of HbR concentration by measuring the variations of light absorption by the explored tissues.

Secondary Measures

  • Oxyhemoglobin (HbO) variations of acute stroke patients
    • Time Frame: Day 0
  • Deoxyhemoglobin (HbR) variations of acute stroke patients
    • Time Frame: Day 0
  • Oxyhemoglobin (HbO) variations of subacute stroke patients
    • Time Frame: Day 0
  • Deoxyhemoglobin (HbR) variations of subacute stroke patients
    • Time Frame: Day 0
  • Oxyhemoglobin (HbO) variations using different mathematical treatments.
    • Time Frame: Day 0
  • Deoxyhemoglobin (HbR) variations using different mathematical treatments.
    • Time Frame: Day 0

Participating in This Clinical Trial

Inclusion Criteria

  • Acute stroke group, subacute stroke group, and control group: – Age 50 to 80 years – Affiliated with a social security plan – Able to walk 20 meters unassisted – Acute Stroke and Subacute Stroke Group: – Stroke onset less than 14 days (for the acute stroke group) or between 14 days and 6 months (for the subacute stroke group) – Stroke located in the left or right middle cerebral artery. Exclusion Criteria:

  • Acute stroke group, subacute stroke group, and control group: – Person under guardianship or curatorship – Refusal to sign informed consent – Known rheumatologic or cardiologic history – Medication that alters the vigilance and may affect walking (high dose psychotropic drugs, antispastic drugs). – Acute stroke group and subacute stroke group: – History of symptomatic stroke – Previous neurological disease limiting gait, aphasia or impaired cognitive function (mild cognitive dementia, Alzheimer's or Parkinson's disease) – Ambulatory functional category < 3 – Control group: neurological medical history

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Centre Hospitalier Régional d’Orléans
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Andreea AIGNATOAIE, Principal Investigator, CHR d’Orléans
  • Overall Contact(s)
    • Andreea AIGNATOAIE, 0238229947, andreea.aignatoiae@chr-orleans.fr

References

Hermand E, Tapie B, Dupuy O, Fraser S, Compagnat M, Salle JY, Daviet JC, Perrochon A. Prefrontal Cortex Activation During Dual Task With Increasing Cognitive Load in Subacute Stroke Patients: A Pilot Study. Front Aging Neurosci. 2019 Jul 2;11:160. doi: 10.3389/fnagi.2019.00160. eCollection 2019.

Hawkins KA, Fox EJ, Daly JJ, Rose DK, Christou EA, McGuirk TE, Otzel DM, Butera KA, Chatterjee SA, Clark DJ. Prefrontal over-activation during walking in people with mobility deficits: Interpretation and functional implications. Hum Mov Sci. 2018 Jun;59:46-55. doi: 10.1016/j.humov.2018.03.010. Epub 2018 Mar 29.

Holden MK, Gill KM, Magliozzi MR, Nathan J, Piehl-Baker L. Clinical gait assessment in the neurologically impaired. Reliability and meaningfulness. Phys Ther. 1984 Jan;64(1):35-40. doi: 10.1093/ptj/64.1.35.

Pelicioni PHS, Tijsma M, Lord SR, Menant J. Prefrontal cortical activation measured by fNIRS during walking: effects of age, disease and secondary task. PeerJ. 2019 May 3;7:e6833. doi: 10.7717/peerj.6833. eCollection 2019.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.